Australia's Immutep extends gain on FDA orphan drug status for cancer drug
16/04/2026 03:24
** Shares of Australian biotechnology firm Immutep IMM.AX rise as much as 22.2% to A$0.075, their highest since March 6 ** Stock extends gain from the previous session when it closed 84.6% higher after receiving U.S. FDA Orphan Drug Designation for Eftilagimod Alfa to treat a type of cancer ** About 154.1 mln shares change hands, 3.1x the 30-day average of 50.2 mln ** Stock down 81.3% YTD, including current moves (Reporting by Jasmeen Ara Shaikh in Bengaluru) ((Jasmeenaraislam.Shaikh@thomsonreuters.com;))
Recent news on Immutep
See all newsBrief: Immutep Receives NASDAQ Notice Of Minimum Bid Price Non-Compliance
Australia's Immutep extends gain on FDA orphan drug status for cancer drug
Brief: Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue Sarcoma
Brief: Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung Cancer
Brief: Dr Reddy's Says IDMC Recommends Discontinuation Of TACTI-004 Phase III Trial After Interim Futility Analysis